TRULI | LATS1/2 kinase inhibitor

CAS:
 1424635-83-5
Catalog Number:
 10-4295
TRULI chemical structure

Available Options

Size:PriceQuantity 
5 mg$100.00
25 mg$375.00
Request Quote / Bulk / Custom Size
Product Inquiry

TRULI (1424635-83-5) activates the transcriptional activator Yap via inhibition of large tumor suppressor kinases (LATS) 1/2 (IC50 = 0.2 nM; EC50 = 510 nM HEK293A cells).1 It induced the proliferation of murine neonatal cardiomyocytes and human Müller glia in retinal organoids. TRULI reduced tumorigenicity of human chronic myelogenous leukemia cells and increased sensitivity to imatinib treatment.2 It moderated cartilage degeneration in an osteoarthritis model via modulation of ZBTB20.3

References/Citations:

  1. Kastan et al. (2021), Small-molecule inhibition of Lats kinases may promote Yap-dependent proliferation in postmitotic mammalian tissues; Nat. Commun. 12 3100
  2. Klaihmon et al. (2024), Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib; Sci. Rep. 14 3993
  3. Hao et al. (2025), LATS1-modulated ZBTB20 perturbing cartilage matrix homeostasis contributes to early-stage osteoarthritis; Bone Res. 13 33
1424635-83-5, LATS inhibitor, LATS1/2 inhibitor, TRULI, TRULI supplier, YAP activator
CAS:
1424635-83-5
Catalog Number:
10-4295
Activity:
LATS1/2 kinase inhibitor
Chemical Names:
N-(3-Benzyl-1,3-thiazol-2-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide
Molecular Weight:
334.40
Molecular Formula:

C18H14N4OS

Solubility:
Soluble in DMSO (50 mg/ml)
Physical Properties:
White solid
Purity:

>98% HPLC
NMR: (Conforms)

Storage Temperature:
-20°C
Stability:
Stable for up to 2 years when stored as supplied @ room temperature. Solutions in DMSO may be stored at -20°C for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

TRULI (1424635-83-5) activates the transcriptional activator Yap via inhibition of large tumor suppressor kinases (LATS) 1/2 (IC50 = 0.2 nM; EC50 = 510 nM HEK293A cells).1 It induced the proliferation of murine neonatal cardiomyocytes and human Müller glia in retinal organoids. TRULI reduced tumorigenicity of human chronic myelogenous leukemia cells and increased sensitivity to imatinib treatment.2 It moderated cartilage degeneration in an osteoarthritis model via modulation of ZBTB20.3

References/Citations:

  1. Kastan et al. (2021), Small-molecule inhibition of Lats kinases may promote Yap-dependent proliferation in postmitotic mammalian tissues; Nat. Commun. 12 3100
  2. Klaihmon et al. (2024), Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib; Sci. Rep. 14 3993
  3. Hao et al. (2025), LATS1-modulated ZBTB20 perturbing cartilage matrix homeostasis contributes to early-stage osteoarthritis; Bone Res. 13 33

STEM CELL

BOGO